Phathom Pharmaceuticals, Inc. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending June 29, 2021 was 167.28% (a -9.86% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -41.21%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 292.4% (a -38.52% decrease from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending June 29, 2021 was 206.62% (a -11.86% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -43.2% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
206.62% 234.41% 292.7% 363.74%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of Phathom Pharmaceuticals, Inc.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof PHAT including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 167.28% 185.57%
2020 258.05% 284.56% 278.07% 465.87% 292.4%
2019 1040.84% 475.6%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.